TB Events World TB Day 2008 TB & WHO TB Fact Sheet TB Forum Global TB TB & HIV TB & Diabetes TB & Poverty TB & Women TB & Children TB News TB & DOTS TB & Famous Personalities
Sitemap

 


DIABETES MAY IMPAIR TUBERCULOSIS TREATMENT RESPONSE

NEW YORK (Reuters Health) - Patients with tuberculosis and diabetes do not respond as well to tuberculosis therapy as those who are non-diabetic, Dutch researchers report.

The reason for this is unclear, but screening for and aggressively treating diabetes may improve the outcomes of patients receiving tuberculosis therapy, Dr. Reinout van Crevel, from Radboud University Medical Center in Nijmegen, note in the current issue Clinical Infectious Diseases.

The findings stem from a study of 737 Indonesian patients with tuberculosis who were screened for type 2 diabetes, also referred to as adult-onset diabetes, and then followed while receiving tuberculosis therapy.

Overall, 14.8 percent of the subjects had diabetes. Despite initially having more symptoms, the patients with diabetes had tuberculosis that was comparable in severity to that in non-diabetics.

However, after 2 months of treatment, sputum test results were more likely to be positive in diabetic patients --18.1 percent vs. 10.0 percent in non-diabetics. At 6 months, the diabetes were still significantly more likely to have positive sputum test results than the non-diabetic patients, at 22.2 percent vs. 9.5 percent, respectively.
In a related editorial, Dr. Blanca I. Restrepo, from the University of Texas Health Science Center in Houston, comments that the findings "highlight the need for further research aimed at understanding how the current global epidemic of type 2 diabetes mellitus is affecting tuberculosis control and prevention."

SOURCE: Clinical Infectious Diseases, August 15, 2007.

ACTIVE TUBERCULOSIS SHOULD BE TREATED WITH INSULIN:

--Prof. P.V.Rao, Nizam's Institute of Medical Sciences, Hyderabad, India.

Diabetic patients are not only more susceptible to infection but when infections do occur they are more severe as the diabetic is a compromised host. Tuberculosis infection in diabetes mellitus is usually due to reactivation of an old focus rather than through fresh contact. Patients with diabetes mellitus and tuberculosis present with more advanced disease and have more changes in the lower lobes. For these reasons, tuberculosis is described as a complication of diabetes mellitus. In U.K. tuberculosis is quoted first among common infections in diabetes mellitus, although the last UK publication on increased frequency of tuberculosis in diabetes mellitus appeared in 1948. Inspite of successfully eradicating tuberculosis in their communities, the American Thoracic Society and Centers for Disease control cautiously list diabetes mellitus as a special situation, and prescribe chemoprophylaxis with isoniazid in those with diabetes mellitus and positive Heaf test. In populations of developing countries, tuberculosis remains a significant cause of morbidity and mortality in both types of diabetes mellitus. Vulnerability of Type I diabetes mellitus is amply evidenced in many reports from many parts of the world. The 10-year actual risk of acquiring tuberculosis was 24.2% for 116 Type I diabetes mellitus and 4.8 %for the rest in one study from Chile. It was also reported in one study that 30% of the young, undernourished, insulin-requiring and ketosis-resistant diabetics needing increased insulin. Tuberculosis in Type II is not uncommon either, as 5-10% have pulmonary tuberculosis in developing countries. Though tuberculosis is more prevalent in Type I diabetes mellitus, the magnitude of the problem in Type II diabetes mellitus should be considered with no less concern in the purview of Type II diabetes mellitus affecting an overwhelming larger number of people and also emerging as a serious public health problem in developing countries.

 
PANCREATIC ENDOCRINE DEFICIENCY

A high proportion of chronic respiratory failure patients might have intolerance for glucose loading but a normal insulin secretion pattern. However in active pulmonary tuberculosis, immunoreactive insulin, C-peptide and glucose levels before and after glucagon stimulation demonstrated absolute insulin deficiency and more frequent development of severe diabetes mellitus. Hyperglycemia in a study of 51 patients with pulmonary tuberculosis was at first due to relative insulin deficiency coupled with higher pancreatic functional reserve as tuberculosis progressed. The functional disorders of the insular system of the pancreas were more evident in middle-aged and elderly patients with pulmonary tuberculosis. Further, antituberculous therapy (ATT) was also reported to be detrimental to serum C-peptide as well as to the insulin sensitivity in a study. These negative effects on the inherent insulin resistance and rapid loss of pancreatic residual function in chronic tuberculosis warranted exogenous insulin administration in these diabetics. There is one report from Chennai, India that even in a previously not ascertained diabetic, ATT may affect beta-cell function and unmask the diabetic state.

 

TUBERCULOUS PANCREATITIS

Active tuberculosis should be a leading cause differential diagnosis in patients with enlarged pancreas when the usual diagnostic reasoning does not yield conclusive results. Even a clinical diagnosis of insulinoma was no exception for subsequent detection of active abdominal tuberculosis on laparotomy. Tuberculosis is one of the rarer causes of pancreatitis, and only with the development of diabetes mellitus might a chronic pancreatitis of probable tuberculous origin reveal itself. Interestingly, there was a higher prevalence of pulmonary tuberculosis in patients with diabetes mellitus secondary to chronic pancreatitis. Perhaps in most, tuberculosis infections in the pancreas is dormant, even preceding diabetes mellitus.

 
TUBERCULIN TOXICITY ON PANCREAS

Purified protein derivative (PPD) of tuberculin is widely used for induction and study of autoimmunity in vitro-vivo in animals and humans, and many available reports described its direct toxic effects on pancreas. Glucose stimulated insulin-release, and contents of insulin-release and glucagons were reported as markedly reduced in isolated human islets incubated with cytokine-rich supernatants of blood mononuclear cells stimulated with PPD f tuberculin. Such supernatants of blood mononuclear cells stimulated with purified with PPD of tuberculin were more potent cytotoxic to human is lets in inhibiting insulin release than any other known media. At the 12th International Immunology of Diabetes Workshop held during April 1993 in Oriando, Florida, one of the reviews was on the insulitis in the NOD mouse induced by tuberculin antigen in which diabetes onset was delayed by insulin administration. Thioredoxin is a more specific Mycobacterium tuberculosis protein recently identified with functional activity.

 

PITUITARY, THYROID, AND ADRENAL DEFICIENCIES

Glucose, ACTH, cortisol, growth hormone (GH), and prolactin (PRL) in fasting and following insulin -induced hypoglycemia were reported high in 96 pulmonary and 15 hematogenous tuberculosis patients due to stress induced by infections. Higher levels of anti-insulin hormones exhausted eventually due to stress induced by infection. Higher levels of anti-insulin hormones exhausted due to supramaximal stimulation, as measurements of C-peptide as well as T3, T4, TSH, ACTH and the circadian excretion of 17-OCS revealed high frequency of absolute and relative insufficiencies of pituitary, thyroid, and adrenal glucocorticoid functions in pulmonary tuberculosis. Concomitant thyroid treatment benefited 92.8% of such 111 patients with pulmonary tuberculosis suffering from diabetes mellitus. In adolescents with pulmonary tuberculosis, reduced levels of somatotrophic hormone, immunoreactive insulin and 17-keto-steroids were related to impaired physical development evaluated using the main anthropometrical tests. As endocrine insufficiencies in pulmonary tuberculosis were pronounced, blood plasma cortisol /insulin ratio was recommended as a diagnostic marker for dissemination of pulmonary tuberculosis. Supranormal concentrations of substances cross-reactive with insulin (SCIRI) were also frequently associated with nonmalignant pulmonary tissue proliferation as in tuberculosis, which might also contribute to insulin resistance. In all these situations, exogenous insulin not only offsets the possible insulin administration was also known to improve immune responses as demonstrated in alloxan rats.

WEIGHT LOSS

The association between marked weight loss and diabetes mellitus and/or tuberculosis is uncontrolled. Cachexia may not always be the effect of diabetes mellitus or tuberculosis, but also has a formidable causative role in tuberculosis infection and its therapy. To this effect, the clinical evidence abounds. In consonance, animal experiments demonstrated that loss of weight was detrimental, and high protein diet protected from mycobacterium. In diabetes mellitus with tuberculosis, Ahuja's recommendation is to allow calories as for standard weight, or at least 2000-2400 kcal per day irrespective of their absolute weight to ensure that patient is not in negative nitrogen balance, and also to adequately cover the insulin doses prescribed.

 
ADVERSE EFFECTS AND DRUG INTERACTIONS OFANTITUBERCULOSIS THERAPY

Rifampicin accelerates the metabolism of oral hypoglycemic agents, as it is a potent hepatic enzyme-inducing agent. It was also known to cause early hyperglycemia in non-diabetic patients with or without pulmonary tuberculosis, and also to augment intestinal absorption of glucose. Some of the adverse effects of Rifampicin in Type I diabetes mellitus as detailed below may well be applicable to the altered glycemic control in Type II diabetes mellitus, as well. Rifampicin per se, and not tuberculous infection, Isoniazid, or Pyrazinamide, was attributed to the increased insulin requirement in a 54 -year old woman with Type I diabetes mellitus.

Chronic rifampicin treatment manifesting hypercortisolism and unstable glycemic control led to a misdiagnosis of Cushing 's syndrome due to occult ectopic ACTH secretion with long-standing Type I diabetes mellitus and active tuberculosis. However, after withdrawal of rifampicin, his urinary cortisol excretion returned to normal within two weeks, as well as the 24-hour profile and dynamic tests.

Malabsorption of rifampicin was also reported in poorly controlled diabetes mellitus in a 14-year old year old boy with INH resistance. Apart from causing pancreatic hypofunction and peripheral insulin insensitivity, long-term administration of ATT interfered with hydrolysis and absorption of carbohydrates in small intestine in 106 newly detected persons with pulmonary tuberculosis.

A chemotherapeutic regimen supplemented with insulin, glucocorticoids, and folic acid, in particular, improved intestinal carbohydrate absorption in them. The epidemiological, paraclinical and therapeutical viewpoints in 68 diabeticpatients clearly established the efficiency of ATT in annulling the negative influence of the diabetes mellitus -tuberculosis morbid association.

Unfortunately, the liability of these diabetic patients persisted in spite of the best control of tuberculosis by tuberculostatics. Isoniazid antagonizes sulphonylureas and impairs insulin release and action, and rifampicin shortens the plasma half-life of sulphonylureas.

 
HEPATIC DISEASE

In addition to the hepatotoxicity of isoniazid, rifampicin, pyrazinamide the ethambutol, the association of hepatic disease with pulmonary tuberculosis and diabetes mellitus is ubiquitous. Comprehensive examination of 50 patients with pulmonary tuberculosis and diabetes mellitus, confirmed chronic active hepatitis in 3, chronic persistent hepatitis in 8, non-specific reactive hepatitis in 4, live cirrhosis in 3, fatty degeneration in 10 and fibrosis of the liver in 22 patients.

 

CONTRAINDICATIONS FOR ORAL ANTIDIABETIC DRUGS

Sulphonylureas are not indicated in tuberculosis, as it is more chronic and serious of all infections in diabetes mellitus. They are not indicated in diabetes mellitus associated with destruction of pancreas either, which is the extra-pulmonary manifestation of active tuberculosis in many instances. Biguanides are contraindicated, as metformin produces weight loss indicating the role of malabsorption, particularly in high doses, and it is also an anorectic. Biguanides as well as sulphonylureas are contraindicated in hepatic disease, which is a common adverse effect of ATT. Marked weight loss, increasing age, longer duration of diabetes mellitus, higher insulin and caloric needs in tuberculosis are other important indications for withholding oral antidiabetic therapy in diabetes mellitus.

 
AGING

Usual signs and symptoms in tuberculosis may be absent or show only a mild toxic reaction, with absence of fever or cough. Thus, masking of serious infection is likely in diabetes mellitus, and autonomic neuropathy and aging facilitating it. As non-respiratory tuberculosis presentations are atypical or relatively insidious, delayed diagnosis may be crippling or even potentially life threatening. Less favorable course and outcomes of the disease, related to older age and late diagnosis of pulmonary tuberculosis, were registered in 40 cases of Type II as compared to 110 Type I diabetes mellitus. Pulmonary tuberculosis in Type II often runs asymptomatically and slowly, specific changes in the lungs seem limited, and foci of destruction are solitary and large. Adverse reactions to respiratory drugs such as isoniazid were also known to increase with age. The prevalence of tuberculosis infection was 11.3% in 228 Type II diabetes mellitus at a Spanish Health Centre, and the average age of them was 62.6+11.4 years. As the risk tuberculosis increases with age and years of evolution of the disease, protocol use of PPD test in diabetes mellitus and chemoprophylaxis if necessary, was recommended. Elderly individuals aged 60 and older have four to five times the case rate of tuberculosis, and some of their immune deficits of aging could be the cause of tuberculosis, and some of their immune deficits of aging could be reversed by GH and / or IGF-1 treatments demonstrated in humans and primates.

 
DEFECTIVE LUNG DEFENCE

The lungs of diabetics with tuberculosis show defective defence mechanisms in the form of dystrophy of alveolar macrophages, type II alveolocytes and fibroblasts, generalized affection of pulmonary vessels, intensive fiber formation and disorganization of the pathological process. Diabetes mellitus, and tuberculosis also increase the likelihood of severe laryngeal injury.

 

RARER MANIFESTATIONS OF TUBERCULOSIS

Papulonecrotic tuberculid tuberculosis of maxilla, zygoma and sinus, spindle cell pseudotumors in the lungs, visceral neuropathy, hyperosmolar hyperglycemic nonketotic coma, and ketoacidosis are some of the rare presentatations recorded in compromised diabetic hosts. Cutaneous infections caused by Mycobacterium chelonae after self-injection of insulin using jet injector were another rare report of Mycobacterium related complications in diabetes mellitus. The lesions are painful, indurated, purplish, multiple at the injection sites, and the culture of pus eventually grows the atypical Mycobacterium resistant to usual ATT. In diabetes mellitus, a superinfection is rarely missed or a misdiagnosis of tuberculosis is not uncommonly made for silicosis, adrenal or disseminated histoplasmosis, meliodosis, aspergilillosis, or coccidiodomycossis. Such overzealous diagnosis of tuberculosis is most certainly justified in Indian context. The dictum that if diabetes mellitus is not controlled, look for tuberculosis and if tuberculosis is not controlled, look for diabetes mellitus, still holds good.

 
Risk of developing TB disease

The following figures show the risk of developing TB disease for three different groups of people.
 
Figure 1.6
 
TB infection and no risk factors(about 10% over a lifetime) TB infection and
diabetes(about 30% over a lifetime)
TB infection andHIV infection(a very high risk over a lifetime)

For people with TB infection and no risk factors , the risk is about 5% in the first two years after infection and about 10% over a lifetime.

For people with TB infection and diabetes, the risk is 3 times as high, or about 30% over a lifetime.

For people with TB infection and HIV infection , the risk is about 7% to 10% PER YEAR, a very high risk over a lifetime.

 

In an HIV-infected person, TB disease can develop in either of two ways. First, a person who has TB infection can become infected with HIV and then develop TB disease as the immune system is weakened. Second, a person who has HIV infection can become infected with M. tuberculosis and then rapidly develop TB disease.

 
CONCLUSIONS:

The recommendations are that diabetes mellitus and tuberculosis should be treated with insulin injection, or in case a diabetic with tuberculosis is on oral hypoglycemic agents, it is necessary to switch to insulin.


DIABETES MELLITUS, TUBERCULOSIS AND INSULIN
-- Dr.P.V.RAO

  1. Chronic and severe tuberculous infection
    · Increased susceptibility in diabetes mellitus
    · Reactivation of old focus of infection
    · More cavitations, smear-or-culture positivity
    · Deceptively mild or absent toxic symptoms and signs
    · Ineffective chemotherapy in hyperglycemia
  2. Loss of tissue and function of pancreas
    · Pancreatic endocrine deficiency
    · Tuberculous pancreatitis
    · Tuberculin toxin on the pancreas
  3. Requirement of high calorie, high protein diet
    · Counter negative nitrogen balance
    · Facilitate tuberculous therapy
    · Prevent further infection, reactivation
  4. Interactions and adverse effects of antituberculous drugs
    · Rifampicin accelerates the metabolism of antidiabetic drugs
    · Rifampicin per se may increase insulin requirements
    · Isoniazid antagonizes sulphonylureas
    · Isoniazid may rarely cause pancreatitis
    · Interference with intestinal absorption of carbohydrates
  5. Associated hepatic disease
    · With tuberculosis and/or diabetes mellitus
    · Induced by antituberculous therapy
  6. Contraindications for oral antidiabetic drugs
    • For sulphonylureas
      • Tuberculosis, a serious intercurrent illness
      • Pancreatic disease
      • Hepatic disease
    • For bigunides
      • Loss of appetite
      • Loss of weight
      • Glucose malabsorption
  7. Aging
    · Augments susceptibility to tuberculosis
    · Masks tuberculous infection
    · More severe Beta-cell dysfunction
    · Long duration of diabetes mellitus
    · Labile diabetic control
  8. Other factors in diabetes mellitus -tuberculosis association
    · Anti-insulin stress hormone induced by infection
    · Requirement for thyroid or glucocorticoid supplement
    · Supernormal concentrations of insulin antagonists
    · Possible improvement of immune deficits by insulin
    · Defective lung defence mechanisms, laryngeal injury
    · Commonality of rare forms of tuberculosis.
 
Feedback | Legal Disclaimer
 
 

An initiative in India by Sandoz Business Unit
Copyright© 2004, All rights reserved

 
Site developed and maintained by E Vision Technologies